Guinea tests Canadian-developed Ebola vaccine in hot spot

People living in Guinea's worst Ebola-affected region have started receiving the Canadian-developed experimental vaccine in the hopes it will quell spread.

Doctors used the same ring strategy to eradicate smallpox

Canadian-developed Ebola vaccine in hotspot


6 years ago
Guinea's worst Ebola-affected region has started receiving experimental vaccine 1:55

People living in Guinea’ s worst Ebola-affected region have started receiving the Canadian-developed experimental vaccine in the hopes it will quell spread.

The World Health Organization and Guinea’s government plan to vaccinate about 10,000 adults within a six to eight week period.

The field trial will vaccinate family members and other close contacts of recently infected patients to create a "ring of immunity" to stop the virus from spreading. Doctors used the same strategy of vaccinating those at greatest risk first to eradicate smallpox.

So far, the Canadian-developed Ebola vaccine has been given to some volunteer health-care workers.

"It is has been demonstrated that it has appropriate safety profile and it induces an antibody response in the bodies of the people who have been immunized, but we don't know if it works," Dr. Marie-Paule Kieny, WHO’s assistant director general and the agency's head of research and development for Ebola said from Amsterdam.

"It is the last step for the vaccine before it is used and registered as a commercial product."

The Ebola outbreak in West Africa has killed more than 10,200 people. The outbreak seems to be waning overall but the goal continues to be trying to reach zero cases as soon as possible.

Guinea had 95 new confirmed cases, the country’s highest weekly total for 2015, WHO said separately Wednesday.

"Key response indicators for Guinea suggest that there remain significant challenges to overcome before transmission is brought under control."

Sakoba Keita, national coordinator of the fight against Ebola in Guinea, said combining control measures already in place with a safe and effective vaccine "will allow us to close this trying chapter and start rebuilding our country."

The first team arrived in a small village in western Guinea’s Coyah prefecture on western Guinea, a viral hot spot, on March 23, where WHO says they received an excellent response from the community.

Kieny said so far people in the village have had excellent discussions and are willing to roll up their sleeves for the shots.

"The community was very welcoming," Kieny said. "They want us to come back because the team didn't have the time to vaccinate all the people who wanted to be vaccinated."

Fear and resistance linger

Previously, people in Guinea have attacked health-care workers with stones and machetes amid rumours that they were plotting to contaminate them with the virus.

"The fear and the resistance towards all Ebola-related intervention is still hanging in Guinea," said Jean-Paul Jemmy, medical coordinator of operations with Doctors Without Borders in Geneva. "We hope that with the proper community engagement those can be mitigated."

Jemmy and Kieny said they hope the vaccine will be an important tool to add to behaviour changes and care of patients.

The medical charity, which is helping to coordinate and fund the trial, said participation is voluntary, confidential and free.

WHO is the sponsor of the study. Results could be available as early as July 2015.

The trial is also funded by the Research Council of Norway through the Norwegian Institute of Public Health; the Canadian government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre and Department of Foreign Affairs, Trade and Development; and WHO, with support from the Wellcome Trust, United Kingdom. 

With files from CBC's Christine Birak and Reuters


To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Become a CBC Member

Join the conversationCreate account

Already have an account?